John Libbey Eurotext

European Journal of Dermatology


Management of mucous membrane pemphigoid: a literature review and update Volume 32, numéro 3, May-June 2022


  • Figure 1.
  • Figure 2.
  • Figure 3.
  • Figure 4.


1 Department of Oral and Craniofacial Health Sciences, College of Dental Medicine, University of Sharjah Department of Oral Medicine and Oral Surgery, Faculty of Dentistry, Jordan University of Science and Technology
2 Department of Oral Diagnosis and Medicine, Hokkaido University Graduate School of Dental Medicine, Hokkaido, Japan
Reprints: Mohammad S. Alrashdan

Mucous membrane pemphigoid (MMP) is a rare group of heterogeneous chronic autoimmune diseases that predominantly manifest as blistering of the mucous membranes. MMP lesions often heal with scarring, which may result in impaired organ function and significant morbidity. The exact pathogenic mechanisms of MMP are still largely unknown while the diagnosis is based on a combination of clinical, histological and immuno-pathological findings. Several treatment modalities of MMP are available and are reported in the literature, however, such treatment options are principally guided by expert opinions and descriptive reports. Non-specific immunosuppression, especially corticosteroids, remains the mainstay of treatment, which often leads to severe adverse effects. Therefore, safer and more effective therapeutic modalities are required. This comprehensive literature review outlines the current knowledge and recent advances in the field of MMP management, with particular emphasis on the oral variant of MMP.